OTC · Health care

Kaya Holdings, Inc. (KAYS)

It posted a net loss of $11.7M. In fiscal 2024 capital spending exceeded operating cash flow by $858K. At September 30, 2025 it held $26.1K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 20, 2025.

Watch KAYS in 60 seconds

Price

$0.00

0.00% on the day · September 25, 2026

52-week range $0.00 to $0.06

Market cap

$68.6K

What Kaya Holdings, Inc. does

Kaya Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker KAYS.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2024	$7.1K	-$2M	-$2.1M	-$0.07	-$858K
2023	$196.3K	-$1M	$1.6M	$0.01	n/a
2022	$685.4K	-$1.7M	-$3.6M	n/a	n/a
2022	$889.9K	-$1.4M	$9.7M	n/a	-$1.1M
2020	$1M	-$1.8M	-$12.3M	-$0.92	n/a
2019	$1M	-$2.3M	$7.5M	$0.02	-$794.5K

Full financial statements: income, balance sheet and cash flow

Where KAYS ranks in Health care

Revenue$7.1K

#734 of 742 in Health care · Bottom 1%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Kaya Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

March 30, 2026
Late annual report notice NT 10-K
November 28, 2025
Executive or director change 8-K
November 20, 2025
Quarterly report 10-Q · period to September 30, 2025Revenue rose 80% to $5.4K versus the same quarter last year; diluted EPS -$0.06 versus -$0.10.
November 13, 2025
Late quarterly report notice NT 10-Q
October 23, 2025
Change in control 8-K
September 22, 2025
Other event 8-K
August 27, 2025
Quarterly report 10-Q · period to June 30, 2025Revenue was $10.1K; diluted EPS -$0.06 versus $0.00.
August 13, 2025
Late quarterly report notice NT 10-Q
May 21, 2025
Quarterly report 10-Q · period to March 31, 2025Revenue fell 75% to $7.1K versus the same quarter last year; diluted EPS -$0.04 versus -$0.01.
May 19, 2025
Annual report (amended) 10-K/A · period to December 31, 2024Revenue fell 96% to $7.1K versus the prior year; diluted EPS -$0.07 versus $0.01.

All filings on SEC EDGAR

Questions about KAYS

What does Kaya Holdings, Inc. do?

Kaya Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker KAYS.

Is Kaya Holdings, Inc. profitable?

No. Over the twelve months to September 30, 2025 it reported a net loss of $11.7M.

When did Kaya Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 20, 2025. It covers the period to September 30, 2025. Its newest filing of any kind is the late annual report notice from March 30, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare KAYS with

Compare KAYS with any company

Follow KAYS

Get an email when Kaya Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow KAYS: get an email when it files

Where the numbers come from

Financial figures are the values Kaya Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.